Clinical Research Directory

Inclusion Criteria: 1. Males and females aged 50-85 years old at time of on-site visit. (ages 81-85 will be assessed on a per case basis by the principal investigator) 2. Signed Informed consent. 3. Willing \& able to comply with study procedures (including SIMBA capsule ingestion) and have study assessments performed. 4. Able to swallow a size-00 capsule (25mm length) in OFF state. 5. Diagnosis of idiopathic PD (Clinically Probable PD), including documented levodopa responsiveness. 6. Treatment with an immediate release levodopa formulation during the day at a stable dose for at least 2 months prior to enrollment. Exclusion Criteria: 1. Any risk of capsule non-excretion related to intercurrent gastrointestinal conditions. 2. Use of any medications in the week prior to the on-site study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function. 3. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration, e.g., SDQ score \> 4. 4. Any concomitant or previous treatment (\<2 months from on-site study visit) with significant anti-inflammatory or immune suppressant medication, e.g., DMARDs, biologicals or systemic corticosteroids, except non-chronic PRN use of an NSAID and/or 5-ASA (mesalazine) treatment. 5. Active cancer within 5 years. 6. Clinically significant immune deficiency (according to Investigator's judgement). 7. Antibiotic use (except for local use), ≤12 weeks prior to on-site study visit, or Fecal Microbiota Transplantation anytime in medical history. 8. Use of prebiotics, or probiotics ≤2 weeks prior to the on-site study visit. 9. Dementia in medical history. 10. Insulin-dependent diabetes mellitus. 11. Current Psychosis episode by clinical judgement based on anamnesis. 12. Pregnancy. 13. Alcohol or drug abuse. 14. Deep brain stimulation or Duodopa/Lecigon treatment.